Indivior PLC presented new findings at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting on June 19, 2025. A post hoc analysis revealed that patients with heavier fentanyl use experienced clinically meaningful improvements in opioid abstinence when treated with a 300 mg maintenance dose of SUBLOCADE, compared to the 100 mg dose.
While the 300 mg dose did not show a statistically significant advantage over 100 mg for weekly abstinence in the overall population, the results suggest that higher doses of SUBLOCADE may offer better outcomes for individuals with high levels of fentanyl use. No new safety concerns were identified with either the 100 mg or 300 mg maintenance doses.
These findings aim to provide clinicians with additional data that can inform treatment strategies and support patients with intense fentanyl use patterns on their journey to recovery. The study reinforces Indivior's commitment to advancing understanding and treatment options for opioid use disorder.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.